Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.Claudio Vernieri, Leonardo Provenzano, Mario Giuliano et al.|Journal of Clinical Oncology|2024Cited by 7
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Carmine De Angelis, Antonio Giordano et al.|EClinicalMedicine|2025Cited by 7
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.Claudio Vernieri, Maria Vittoria Dieci, Roberta Caputo et al.|Journal of Clinical Oncology|2025Cited by 1
Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-AnalysisRoberto Buonaiuto, Carmine De Angelis, Mario Fordellone et al.|SSRN Electronic Journal|2025Cited by 0
Abstract P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 studyFrancesca Ligorio, Claudio Vernieri, Leonardo Provenzano et al.|Clinical Cancer Research|2025Cited by 0